University of Cyprus

About: University of Cyprus is a education organization based out in Nicosia, Cyprus. It is known for research contribution in the topics: Large Hadron Collider & Context (language use). The organization has 3624 authors who have published 15157 publications receiving 412135 citations.

Market Effects of Changes in Consumers' Social Responsibility

Abstract: In a duopoly model of vertical differentiation, we study market equilibrium and the resulting social welfare following an increase in the consumer's willingness to pay (WTP) for products sold by socially responsible manufacturers. Different types of such changes emerge depending on their effects on consumer heterogeneity. We show that, in most cases, increases in the consumers' social consciousness yield higher profits to socially responsible firms and may lead to higher levels of social welfare, provided that the market structure is left unchanged. However, when an increase in the consumer's social consciousness changes the market structure, welfare may fall, while the duopolists' profits rise. The resulting tension between private and social interest calls for a cautious attitude toward information campaigns aimed at increasing the consumer's social consciousness.

Observation of exclusive dijet production at the Fermilab Tevatron p̄p collider

Abstract: The authors present the first observation and cross section measurement of exclusive dijet production in {bar p}p interactions, {bar p}p {yields} {bar p} + dijet + p. Using a data sample of 310 pb{sup -1} collected by the Run II Collider Detector at Fermilab at {radical}s = 1.96 TeV, exclusive cross sections for events with two jets of transverse energy E{sub T}{sup jet} {ge} 10 GeV have been measured as a function of minimum E{sub T}{sup jet}. The exclusive signal is extracted from fits to data distributions based on Monte Carlo simulations of expected dijet signal and background shapes. The simulated background distribution shapes are checked in a study of a largely independent data sample of 200 pb{sup -1} of b-tagged jet events, where exclusive dijet production is expected to be suppressed by the J{sub z} = 0 total angular momentum selection rule. Results obtained are compared with theoretical expectations, and implications for exclusive Higgs boson production at the pp Large Hadron Collider at {radical}s = 14 TeV are discussed.

Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis

Abstract: Background Biological therapies have improved the care of patients with ulcerative colitis (UC). Tofacitinib, an oral small-molecule Janus kinase inhibitor, is potentially a new treatment option. Aim To comparatively assess efficacy and harm of tofacitinib and biologics (infliximab, adalimumab, golimumab and vedolizumab) in adult patients not previously exposed to TNF antagonists. Methods We performed a comprehensive search of PubMed, Embase, Scopus, clinical trial registries, regulatory authorities' websites and major conference proceedings, through August 2017, to identify randomised, placebo-controlled or head-to-head trials assessing tofacitinib or biologics as induction and/or maintenance therapy in moderate-to-severe UC. Two reviewers independently extracted study data and outcomes, and investigated each trial's risk-of-bias. We used conventional meta-analysis to synthesise direct evidence, and network meta-analysis for adjusted indirect treatment comparisons. Results Fifteen randomised, double-blind, placebo-controlled trials (n = 3130) contributed data for induction: All treatments are superior to placebo. Indirect treatment comparisons showed that infliximab is better than adalimumab (OR: 2.01, 95% CI: 1.36-2.98) and golimumab (1.67, 1.08-2.59) in clinical response, better than adalimumab (2.10, 1.21-3.64) in clinical remission, and better than adalimumab (1.87, 1.26-2.79) and golimumab (1.75, 1.13-2.73) in mucosal healing. No indirect comparisons between tofacitinib and biologics reached statistical significance. Nine studies (n = 1776) contributed maintenance data showing that all treatments have higher clinical efficacy than placebo. Safety analyses indicated no increased rates of adverse events for the treatments under evaluation (except for infliximab), while vedolizumab may have an advantage regarding the occurrence of serious adverse events. Conclusions Tofacitinib and biologics are efficacious and safe for UC. Further high-quality research is warranted to establish the best therapeutic option.